Haemonetics annual gross margin
2010
2011
2012
2013
2014
2015
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Haemonetics's gross margin was 59.04% for fiscal 2026.
View full Haemonetics company overview| Fiscal year | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| 2026 | 2026-03-28 | 59.04% | +4.00 pp |
| 2025 | 2025-03-29 | 55.04% | +2.21 pp |
| 2024 | 2024-03-30 | 52.83% | +0.20 pp |
| 2023 | 2023-04-01 | 52.63% | +1.74 pp |
| 2022 | 2022-04-02 | 50.90% | +5.19 pp |
| 2021 | 2021-04-03 | 45.70% | −3.31 pp |
| 2020 | 2020-03-28 | 49.02% | +5.86 pp |
| 2019 | 2019-03-30 | 43.15% | −2.42 pp |
| 2018 | 2018-03-31 | 45.57% | +2.86 pp |
| 2017 | 2017-04-01 | 42.71% | −5.00 pp |
| 2015 | 2015-03-28 | 47.72% | −2.19 pp |
| 2014 | 2014-03-29 | 49.91% | +1.91 pp |
| 2013 | 2013-03-30 | 48.00% | −2.73 pp |
| 2012 | 2012-03-31 | 50.73% | −1.76 pp |
| 2011 | 2011-04-02 | 52.49% | +0.20 pp |
| 2010 | 2010-04-03 | 52.29% | — |
| Fiscal quarter | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| Q1 2027 | 2026-06-27 | 59.76% | −0.06 pp |
| Q4 2026 | 2026-03-28 | 57.23% | −1.17 pp |
| Q3 2026 | 2025-12-27 | 59.71% | +4.18 pp |
| Q2 2026 | 2025-09-27 | 59.50% | +5.25 pp |
| Q1 2026 | 2025-06-28 | 59.82% | +7.78 pp |
| Q4 2025 | 2025-03-29 | 58.39% | +7.15 pp |
| Q3 2025 | 2024-12-28 | 55.53% | +2.63 pp |
| Q2 2025 | 2024-09-28 | 54.25% | +0.66 pp |
| Q1 2025 | 2024-06-29 | 52.03% | −1.69 pp |
| Q4 2024 | 2024-03-30 | 51.24% | −0.09 pp |
| Q3 2024 | 2023-12-30 | 52.90% | +0.91 pp |
| Q2 2024 | 2023-09-30 | 53.59% | +0.52 pp |
| Q1 2024 | 2023-07-01 | 53.73% | −0.69 pp |
| Q4 2023 | 2023-04-01 | 51.33% | −0.11 pp |
| Q3 2023 | 2022-12-31 | 51.98% | −1.36 pp |
| Q2 2023 | 2022-10-01 | 53.07% | +1.99 pp |
| Q1 2023 | 2022-07-02 | 54.41% | +7.12 pp |
| Q4 2022 | 2022-04-02 | 51.44% | +15.08 pp |
| Q3 2022 | 2022-01-01 | 53.34% | +3.31 pp |
| Q2 2022 | 2021-10-02 | 51.08% | +0.60 pp |
| Q1 2022 | 2021-07-03 | 47.30% | +1.26 pp |
| Q4 2021 | 2021-04-03 | 36.35% | −11.26 pp |
| Q3 2021 | 2020-12-26 | 50.03% | +0.58 pp |
| Q2 2021 | 2020-09-26 | 50.48% | +0.19 pp |
| Q1 2021 | 2020-06-27 | 46.03% | −2.57 pp |
| Q4 2020 | 2020-03-28 | 47.61% | +3.00 pp |
| Q3 2020 | 2019-12-28 | 49.45% | +4.50 pp |
| Q2 2020 | 2019-09-28 | 50.28% | +3.96 pp |
| Q1 2020 | 2019-06-29 | 48.61% | +12.31 pp |
| Q4 2019 | 2019-03-30 | 44.61% | −0.09 pp |
| Q3 2019 | 2018-12-29 | 44.95% | −2.61 pp |
| Q2 2019 | 2018-09-29 | 46.32% | −0.07 pp |
| Q1 2019 | 2018-06-30 | 36.30% | −7.16 pp |
| Q4 2018 | 2018-03-31 | 44.69% | — |
| Q3 2018 | 2017-12-30 | 47.55% | — |
| Q2 2018 | 2017-09-30 | 46.39% | — |
| Q1 2018 | 2017-07-01 | 43.45% | — |
Over the last five reported fiscal years, Haemonetics's gross margin increased from 45.70% to 59.04%, a change of +13.33 percentage points. The latest reported quarter, Q1 2027, shows 59.76%.
Gross margin measures the percentage of revenue remaining after the direct costs of producing goods or services. It helps show how efficiently a company turns sales into gross profit before operating expenses.
TickerStat calculates gross margin as SEC-reported gross profit divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Haemonetics filings at SEC.gov ↗